Press Releases
Events

 

 

DOBI Medical International Holds First International Symposium in Europe

Return to Press Releases

October 4, 2004, Mahwah, NJ – DOBI Medical International, Inc. announced today that it hosted the first annual “European Symposium in Optical Breast Imaging” from September 17-19 at Cernobbio, Lake Como, Italy to review the latest information on DOBI Medical’s ComfortScan™ system. The ComfortScan system is an optical breast imaging device designed to help detect tumor angiogenesis (abnormal blood vessel growth) which is often associated with breast cancer. The symposium was attended by seventeen prominent medical imaging device distributors representing more than twenty countries in Europe and the Middle East.

The Symposium’s featured keynote speaker was Dr. Vincent Li, Scientific Director of the Angiogenesis Foundation in Cambridge, Massachusetts - a global, non-profit institute for research and education in the angiogenesis field. Dr. Li also has extensive clinical experience with innovative technologies as Director of the Angiogenesis Clinic, Brigham & Women’s Hospital. His presentation highlighted the role that angiogenesis plays in the human body and reviewed data that underscored the utility of tumor angiogenesis in the breast as a marker for the detecting cancer.

Several other presentations, including such topics as the principles of optical imaging, an overview of DOBI Medical’s ComfortScan technology, and the company’s clinical results to date, were also presented by various company executives.

“This symposium was an important milestone for the company in terms of fulfilling our goal of building long-term partnerships with quality distributors outside of the United States,” said Denis O’Connor, Senior Vice President of Marketing, Sales and Service of the company.

DOBI Medical is planning to host additional symposiums over the next several years. The next event is slated to take place in Latin America during the first half of 2005 in conjunction with the conclusion of a large clinical trial evaluating the ComfortScan system in Brazil.

About DOBI Medical International, Inc.
DOBI Medical is a development stage medical imaging company working to create a new means for the improved diagnosis of cancer through the detection of abnormal vascularization ("angiogenesis") associated with tumors. DOBI Medical International’s first application of the technology is the ComfortScan system, a gentle, non-invasive, and non-ionizing, optical imaging system designed to assist physicians in the detection and management of breast cancer. The ComfortScan system is intended to achieve this by providing new, physiology-based images of abnormal vascularization in the breast that are not readily available today. The ComfortScan system is limited to investigational use and is not currently commercially available in the United States.


CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS

רוני באריל מעצבת פנים. משרד מעצבי פנים

Statements contained in this press release may contain information that includes or is based upon certain "forward-looking statements" relating to our business. These forward-looking statements represent management's current judgment and assumptions, and can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements are frequently accompanied by the use of such words as "anticipates," "plans," "believes," "expects," "projects," "intends," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors, including without limitation, those relating to our ability to timely and successfully complete our patient clinical trials; our ability to timely and successfully complete and submit our premarket approval application to the FDA; the timely and final approval by the FDA of our ComfortScan system as a adjunct to mammography, which approval in the U.S. cannot be assured; our ability to secure the additional financing adequate to execute our business plan; the success of product development and research efforts; our ability to timely meet U.S. and foreign government laws and industry standards; our ability to meet U.S. and foreign medical device quality regulation standards required to maintain our CE Mark, ISO, UL and FDA export certifications; our ability to timely deliver our products into international markets; the acceptance and use of our ComfortScan system by physicians, imaging clinics, and patients; our ability to meet the performance milestones and obtain the funding to close on the second tranche of the private placement completed in December, 2003; and our ability to obtain third party reimbursement from U.S. and foreign government and private payers.
Any one of these or other risks, uncertainties, other factors, or any inaccurate assumptions may cause actual results to be materially different from those described herein or elsewhere by us. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission, which we strongly urge you to read and consider, including our 2003 Annual Report on Form 10-KSB, our Second Quarter Report 2004 on Form 10-QSB, and our Registration Statement on Form SB-2 declared effective September 27, 2004, all of which may be accessed from our website at igaot.pt. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above and elsewhere in our reports filed with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

 

 

Return to Press Releases

For further information:
Please contact: Michael Jorgensen, Chief Financial Officer
201-760-6464
mike@igaot.pt

DOBI Medical International
1200 MacArthur Blvd.
Mahwah, New Jersey 07430
Voice: (201) 760 6464
Fax: (201) 760 8860
e-mail: information@igaot.pt

 
 


calendario | newsletter | relacoes | atribuicoes | acidentesincidentes | legisot | reflegisd | apresentacao | missao | contactos
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 1 | 2 | 3 | 4 | 5